Background/aim: Estrogen receptor (ER)-negative [ER(-)] invasive breast cancers (IBCs) are known to be more aggressive than their ER(+) counterparts. This is less well defined for ductal carcinoma in situ (DCIS). This study investigated the outcomes following the treatment of ER(-) DCIS.
Patients And Methods: A total of 103 ER(-) DCIS patients diagnosed between 2004-2018 were retrospectively analyzed. Median follow-up was 63.9 months. Statistical analysis included descriptive statistics, non-parametric tests, T-test, logistic regression. The outcomes were compared to a group of 102 ER(+) DCIS patients from our institution.
Results: Any breast event (BE) occurred in 10 (9.7%) patients at a median of 3.2 (1.7-7.2) years. The incidence of ipsilateral breast events (IBEs) was 5.8% (6/103). All IBE cases were ER(-) DCIS. All (n=4) contralateral breast events (CBEs) were ER(+) including 3 IBCs. Cumulative incidence of any BEs at 1, 2, and 5 years was 0%, 1.1%, and 9.1%, respectively. Among patients with ER(-) DCIS who developed BE, breast conserving surgery (BCS) had been performed for the initial DCIS in 90% of cases. In those without any BE, the BCS rate (vs. mastectomy) was 58.1% (p=0.08). Adjuvant radiotherapy after BCS was used less often among patients with vs. without subsequent BE (55.5% vs. 77.4%) (p=0.22). Predictors for BE occurrence were not identified. The incidence of any BE among patients with ER(+) DCIS was 6.9% and was not significantly different compared to ER(-) DCIS group (p=0.46).
Conclusion: ER(-) DCIS outcomes were similar to our institutional ER-positive DCIS group and the previously reported ones for predominantly ER-positive DCIS cohorts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.16591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.
Breast Cancer Res Treat
January 2025
Center for Discovery and Innovation (CDI), Hackensack Meridian Health, Nutley, NJ, USA.
Purpose: To study the association between clinicopathologic characteristics of ductal carcinoma in situ (DCIS) and risk of subsequent invasive breast cancer (IBC).
Methods: We conducted a case-control study nested in a multicenter, population-based cohort of 8175 women aged ≥ 18 years with DCIS diagnosed between 1987 and 2016 and followed for a median duration of 83 months. Cases (n = 497) were women with a first diagnosis of DCIS who developed a subsequent IBC ≥ 6 months later; controls (2/case; n = 959) were matched to cases on age at and calendar year of DCIS diagnosis.
Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in Breast Carcinoma.
Iran J Pathol
April 2024
Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background & Objective: Breast cancer is thought to arise from non-invasive breast lesions, such as atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). DCIS is considered a direct precursor of invasive carcinoma. The morphological features alone do not reflect the biological truth of this disease.
View Article and Find Full Text PDFThe diagnostic value of contrast-enhanced ultrasound combined with clinicopathological features in microinvasive ductal carcinoma .
Gland Surg
November 2024
Department of Ultrasound, Chinese People's Liberation Army General Hospital, Beijing, China.
Background: Ductal carcinoma in situ with microinvasion (DCISM) represents 1% of all breast cancer cases and is arguably a more aggressive subtype of ductal carcinoma in situ (DCIS). Preoperative evaluation of DCISM usually relies on core needle biopsy, and non-invasive evaluation methods are relatively limited. This study aims to explore the features of conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) in DCISM and to analyze the US and clinicopathological predictors of infiltrating components.
View Article and Find Full Text PDFComparative long-term oncological outcomes of intraoperative radiotherapy vs. whole-breast irradiation in early breast cancer: a single institute study.
Front Oncol
October 2024
Department of General Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Background: Intraoperative radiation therapy (IORT) and whole breast irradiation (WBI) are both effective adjuvant radiotherapy methods for ductal carcinoma (DCIS) or early-stage breast cancer (BC) patients undergoing breast-conserving surgery (BCS). We aim to evaluate the long-term oncological efficacy and refine patient selection criteria based on our findings.
Methods: Female patients who underwent either IORT or WBI from January 2016 to December 2019, with a minimum follow-up of 12 months were collected.
Spectrum of Ductal Carcinoma In Situ (DCIS) Lesions of the Breast: From Morphology to Molecular Characteristics.
Cureus
September 2024
Department of Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Article Synopsis
- Molecular characteristics of invasive breast cancer and ductal carcinoma in situ (DCIS) are linked to risks of early relapse, prompting a study to explore their correlations through histopathological and biomarker analysis.
- The study analyzed 100 DCIS cases, assessing features such as tumor location, type, and grade, while performing immunohistochemical staining for various receptors and the Ki-67 labeling index to determine molecular subtypes.
- Results indicated most DCIS cases were positive for estrogen and progesterone receptors, with significant correlations found between histopathological characteristics and receptor status, highlighting the potential implications for treatment and prognosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!